Provided by Tiger Trade Technology Pte. Ltd.

Oncolytics Biotech Inc

0.6310
-0.0102-1.59%
Post-market: 0.64990.0189+3.00%19:57 EDT
Volume:611.81K
Turnover:384.76K
Market Cap:80.46M
PE:-1.96
High:0.6521
Open:0.6521
Low:0.6211
Close:0.6412
52wk High:1.42
52wk Low:0.6211
Shares:127.51M
Float Shares:122.97M
Volume Ratio:0.71
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3215
EPS(LYR):-0.3000
ROE:-10187.64%
ROA:-211.24%
PB:-13.05
PE(LYR):-2.10

Loading ...

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Oncolytics Biotech (ONCY)

TIPRANKS
·
Jul 14

Oncolytics Biotech to Meet FDA on Registrational Pathway for REO 033 Colorectal Cancer Trial

Reuters
·
Jul 13

Oncolytics Biotech - Half of Reo 33 Clinical Sites to be Activated This Month; over 20 Patients Pre-identified

THOMSON REUTERS
·
Jul 13

Oncolytics Biotech - to Hold Type D FDA Meeting on Reo 33 Registration Pathway

THOMSON REUTERS
·
Jul 13

Oncolytics Biotech - Initial Reo 33 Part a Tumor Response Update Expected by Year-end 2026; Part B Enrollment May Begin Q1 2027

THOMSON REUTERS
·
Jul 13

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized Ras-mutant Mss Colorectal Cancer Trial

THOMSON REUTERS
·
Jul 13

Oncolytics Biotech - Remaining Reo 33 Sites to be Activated by End of August for Accelerated Enrollment in H2 2026

THOMSON REUTERS
·
Jul 13

Oncolytics Biotech Swaps Auditor Ernst & Young for Baker Tilly

Reuters
·
Jul 09

Sector Update: Healthcare Stocks Advance in Afternoon Trading

MT Newswires Live
·
Jun 17

Oncolytics Gets US Patent for Pelareorep Manufacturing Process

MT Newswires Live
·
Jun 16

Oncolytics secures new patent for pelareorep manufacturing

TIPRANKS
·
Jun 16

Oncolytics Biotech wins new US manufacturing patent for pelareorep, protection through 2044

Reuters
·
Jun 16

Oncolytics Biotech - Announces New U.S. Patent for Pelareorep Manufacturing Process

THOMSON REUTERS
·
Jun 16

Oncolytics Biotech COO John Bearden McAdory files initial beneficial ownership statement

Reuters
·
Jun 04

Oncolytics Biotech director Stephen C. Glover files initial beneficial ownership statement

Reuters
·
Jun 04

Oncolytics promotes John McAdory to COO

TIPRANKS
·
Jun 02

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John Mcadory to Chief Operating Officer

THOMSON REUTERS
·
Jun 02

Oncolytics announces initial data from pelareorep combination study

TIPRANKS
·
Jun 01

Oncolytics Says Preclinical Results Back Further Evaluation of Pelareorep Plus RAS-Targeted Approaches

MT Newswires Live
·
Jun 01

Oncolytics Biotech reports positive preclinical data for pelareorep with RAS-targeted therapies in solid tumor model

Reuters
·
Jun 01